Updated:
Janssen Pharmaceuticals
Janssen Pharmaceuticals is the drug-development arm of Johnson & Johnson, founded in 1953 and headquartered in Titusville, NJ.
Janssen Pharmaceuticals
Janssen Pharmaceuticals originated in 1953 as the pharmaceutical division of Johnson & Johnson, headquartered in Titusville, New Jersey. The unit operates as an R&D-driven organization, with no publicly disclosed founding by named principals separate from the Johnson & Johnson corporate structure. The unit's strategy centers on internal drug discovery and development across therapeutic areas including oncology, immunology, neuroscience, cardiovascular and infectious disease. Janssen has brought to market drugs such as the cancer therapy Darzalex (daratumumab), the immunology drug Stelara (ustekinumab), and the HIV treatment Prezcobix. The geographic footprint spans the United States, Europe, and Asia, with manufacturing and research sites in Belgium, Germany, Japan, and the UK. As an operating company, Janssen employs over 40,000 professionals across R&D and commercial roles, but it does not function as a standalone asset manager or investment vehicle. No recent operational events — such as major acquisitions or divestitures — were verifiable from public sources in the last 24 months beyond routine FDA approvals (per FDA news releases, 2024). Janssen's structural differentiator is its integration within Johnson & Johnson's broader healthcare conglomerate, funding internal R&D through parent-company cash flow rather than external investor capital. This insulates its pipeline decisions from market cycles.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Titusville
Corporate office
Titusville, NJ, United States
Frequently asked questions
Who makes investment decisions at Janssen Pharmaceuticals?
Investment decisions at Janssen Pharmaceuticals are made by its senior leadership and board, ultimately reporting to Johnson & Johnson's corporate management. The unit does not have a publicly disclosed CIO or investment committee separate from the parent company's governance.
Does Janssen Pharmaceuticals function as a standalone family office or asset manager?
No. Janssen Pharmaceuticals is an operating pharmaceutical company within Johnson & Johnson, not a family office or asset manager. It allocates capital to internal drug research and development, not to third-party investments.
What therapeutic areas does Janssen Pharmaceuticals focus on?
Janssen focuses on oncology, immunology, neuroscience, cardiovascular and metabolic diseases, pulmonary hypertension, and infectious diseases. Its pipeline includes both small molecules and biologics.
How is Janssen Pharmaceuticals funded?
Janssen is funded through Johnson & Johnson's corporate cash flow, which derives from pharmaceutical, medical device, and consumer health sales. The unit does not raise external capital from LPs.
Where is Janssen Pharmaceuticals headquartered?
Janssen's corporate headquarters is in Titusville, New Jersey, United States, but its R&D and commercial operations are distributed across sites in Belgium, Germany, Japan, the UK, and elsewhere.
What notable products has Janssen Pharmaceuticals developed?
Key products include Darzalex (daratumumab) for multiple myeloma, Stelara (ustekinumab) for autoimmune diseases, and Prezcobix for HIV. These are marketed globally.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: